Japan grants patent for BioArctic’s Parkinson’s disease antibody

24 Aug 2023
www.pharmaceutical-technology.com
Phase 1Clinical Result
Japan grants patent for BioArctic’s Parkinson’s disease antibody
Preview
Source: Pharmaceutical Technology
BioArctic develops disease-modifying therapies for neurodegenerative ailments. Credit: Chinnapong / Shutterstock.com.
The Japanese Patent Office (JPO) has granted a new drug substance patent for Swedish biopharma company BioArctic’s monoclonal antibody (mAb), BAN0805, to treat Parkinson’s disease.
The patent for the antibody will expire in 2041, with the potential for extension until 2046.
Recommended Reports
Japan grants patent for BioArctic’s Parkinson’s disease antibody
Preview
Source: Pharmaceutical Technology
ReportsJapanese Encephalitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Pla... GlobalData
Japan grants patent for BioArctic’s Parkinson’s disease antibody
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Copanlisib Hydrochloride in B-Cell Non-Hodgkin Lymphoma GlobalData
View allCompanies IntelligenceEisai Co LtdBioArctic ABUppsala UniversityJPO, Inc.View all
BAN0805 selectively attaches to and removes oligomers, which are pathological aggregated forms, as well as protofibrils. It does not impact the alpha-synuclein’s physiological monomer form.
The company plans to advance the mAb as a treatment that stops or decelerates Parkinson’s disease progression.
Findings from a Phase I clinical trial of BAN0805 supported the continued development of BAN0805 in a Phase II study, dosing once a month.
BioArctic CEO Gunilla Osswald stated: “I am delighted to announce that the Japanese Patent Office is granting a new drug substance patent for BAN0805, securing a valuable and extensive period of patent protection.
“This patent further strengthens BioArctic’s patent portfolio and supports our important efforts to develop potential treatments in Parkinson’s disease and other synucleinopathies.”
The company was established in 2003 on the basis of research from Uppsala University in Sweden.
It develops disease-modifying therapies for neurodegenerative ailments such as Alzheimer’s, Parkinson’s and amyotrophic lateral sclerosis.
BioArctic also has a strategic partnership in place with Eisai for Alzheimer’s disease.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.